ClinicalTrials.gg
RecruitingNCT06778473Updated Apr 30, 2025

Intradermal Acupuncture and Self-rehabilitation Program in Patients With Severe Bell's Palsy

An interventional study of Active Intradermal Acupuncture and Sham Intradermal Acupuncture in Bell Palsy, sponsored by Zhangjiagang First People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Zhangjiagang First People's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to assess the effect of intradermal acupuncture(IA) and guided self-rehabilitation management program(GRMP) (either single or combined) for patients with severe Bell's Palsy.

Read the detailed description

After confirming the details of the trial process and signing an informed consent, all participants will be randomly divided into the following four groups: Active IA+GRMP, Active IA+ HE, sham IA+ GRMP, sham IA + HE. They will receive active or sham IA and GRMP or HE until complete recovery or completion of follow up (a duration of 24 weeks).Follow-ups will be done in 4-week, 8-week, 12-week,16-week, 20-week, and 24-week.

02

Conditions studied

  • Bell Palsy

Browse trials for

Keywords

  • Bell Palsy
  • Intradermal acupuncture
  • Self-rehabilitation
03

In context

Bell Palsy

85 studies on the registry are indexed under Bell Palsy; 30 are open to participants now.

This study's planned enrollment of 552 is above the median of 42 across 70 interventional studies indexed under Bell Palsy.

Browse Bell Palsy studies →

Lead sponsor

Zhangjiagang First People's Hospital is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Bell's palsy according to "Clinical Practice Guideline: Bell's Palsy" published by AAO-HNS in 2013;
  • First onset of Bell's palsy with only one side affected;
  • On the 10th day after the onset of palsy, HBGS score ranging from grade IV to VI;
  • According to the latest Chinese Guidelines for Bell's Palsy, within 72 hours of symptom onset for Bell's Palsy, oraling prednisolone 30mg qd for 5 days, followed by tapering to zero in decrements of 5 mg per day;
  • Adults aged 18 years of age or older (no limitation on gender).

Exclusion criteria

Exclusion Criteria:

  • Facial paralysis caused by acoustic neuroma, otitis media, mastoiditis, mumps, Hunter's syndrome, cranial base meningitis, intracranial of cancer or multiple sclerosis;
  • Fear of intradermal acupuncture;
  • allergy to adhesive tape;
  • Severe allergic diseases, significant skin lesions, tumors, and severe or unstable internal diseases involving the cardiovascular, respiratory, endocrine, digestive, or hematological system;
  • Cognitive impairment, mental illness, contagious disease, pregnant and lactating;
  • Previously treated withintradermal acupuncture or participating in other clinical trial within 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
552 participants (estimated)

Study arms

  • Experimental
    "Active intradermal acupuncture" plus "Guided self-rehabilitation management program"

    Active IA will be retained in the acupoints for 72h before being removed, then rested for one day.Participants receive Active IA until full recovery or completion of follow up (a duration of 24 weeks). Participants will be taught and corrected self-rehabilitation techniques by Physical Medicine and Rehabilitation(PMR) therapists at regular outpatient clinic visit (twice weekly for the first 12 weeks, then weekly until full recovery or follow-up completed) and practice at-home therapy and diarize accomplished exercises.

    Device: Active Intradermal Acupuncture · Other: Guided self-rehabilitation management program

  • Experimental
    "Active intradermal acupuncture" plus "Health education"

    Active IA will be retained in the acupoints for 72h before being removed, then rested for one day.Participants receive Active IA until full recovery or completion of follow up (a duration of 24 weeks). Participants will be taught health education content about the disease by PMR therapists at regular outpatient clinic visit (twice weekly for the first 12 weeks, then weekly until full recovery or follow-up completed) and have no homework and keep no daily logs.

    Device: Active Intradermal Acupuncture · Other: Health Education

  • Experimental
    "Sham intradermal acupuncture" plus "Guided self-rehabilitation management program"

    Sham IA will be retained in the acupoints for 72h before being removed, then rested for one day.Participants receive Sham IA until full recovery or completion of follow up (a duration of 24 weeks). Participants will be taught and corrected self-rehabilitation techniques by PMR therapists at regular outpatient clinic visit (twice weekly for the first 12 weeks, then weekly until full recovery or follow-up completed) and practice at-home therapy and diarize accomplished exercises.

    Device: Sham Intradermal Acupuncture · Other: Guided self-rehabilitation management program

  • Sham comparator
    "Sham intradermal acupuncture" plus "Health education"

    Sham IA will be retained in the acupoints for 72h before being removed, then rested for one day.Participants receive Sham IA until full recovery or completion of follow up (a duration of 24 weeks). Participants will be taught health education content about the disease by PMR therapists at regular outpatient clinic visit (twice weekly for the first 12 weeks, then weekly until full recovery or follow-up completed) and have no homework and keep no daily logs.

    Device: Sham Intradermal Acupuncture · Other: Health Education

Interventions

  • DeviceActive Intradermal Acupuncture

    Depending on acupoints' location, φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Insert the Active IA vertically into the acupoint and retain it in the skin. Active IA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be required to press the Active IA 4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours.

  • DeviceSham Intradermal Acupuncture

    Sham intradermal acupuncture will be attached to the acupoints and retained for 72 hours with a day's rest after removal. During the period of sham needle retention,pressing times and frequencies are identical to those in the active intradermal acupuncture group.

  • OtherGuided self-rehabilitation management program

    Self-rehabilitation techniques are taught in individual sessions of about 40 minutes at each outpatient clinic visit, as detailed below: Analysis of the problem, Education, Massage, Facial muscles exercise,Synkinesis or spasticity management, Homework. Participants are requested to perform daily facial muscle exercises as prescribed by the therapist and keep the written diary on a daily basis. The therapists retrieve and evaluate the diaries at each visit.

  • OtherHealth Education

    Health education knowledge about the disease such as etiology, pathology,clinical symptoms of Bell's palsy, Bell's palsy diagnosis and role of medical tests;medication education;complications and sequelae,etc

06

What researchers measure

Primary outcomes

  1. The proportion of participants with complete recovery of facial function at the 24-week.

    The complete recovery of facial function was defined as Sunnybrook Facial Grading System score of 100 points.

    Time frame: Week 24

Secondary outcomes

  1. The proportion of participants with complete recovery of facial function.

    The complete recovery of facial function was defined as Sunnybrook Facial Grading System score of 100 points.

    Time frame: Week4, Week8, Week12, Week16, Week20

  2. The time to complete recovery of facial function.

    The complete recovery of facial function was defined as Sunnybrook Facial Grading System score of 100 points.The recovery time is defined as the time from onset of Bell's palsy until complete recovery of facial function.

    Time frame: Within 24 weeks

  3. The proportion of participants to reach a House-brackmann facial nerve grading system grade of I.

    House-Brackmann facial nerve grading system provides a simple comprehensive evaluation of the resting and moving states of facial muscles, involving a six-point scale with I being normal and VI total, flaccid paralysis.

    Time frame: Week4, Week8, Week12, Week16, Week20, Week24

  4. The changes in Sunnybrook Facial Grading System score from baseline.

    SFGS is based on the evaluation of resting symmetry , degree of voluntary excursion of facial muscles, and degree of synkinesis associated with specified voluntary movement. Possible scores range from 0(total paralysis) to 100(normal).

    Time frame: Week4, Week8, Week12, Week16, Week20, Week24

  5. The changes in Surface Electromyography from baseline.

    The main analytical indicator of sEMG used currently in Bell's palsy detection is the root mean square (RMS)value,quantified as the ratio of the infected side to the unaffected side (%).The higher the ratio, the better the facial nerve function recovery.

    Time frame: Week4, Week12, Week24

  6. The changes in Facial Disability Index physical function subscale from baseline.

    Facial Disability Index(FDI) is a disease-specific, self-report instrument designed to evaluate the degree of disability in patients with facial nerve disorders.FDI includes 2 subscales: the FDI- physical function subscale and the FDI-social/ wellbeing function subscale.Possible scores of every subscale range from 0(worst) to 100(best).

    Time frame: Week4, Week12, Week24

  7. The changes in Social Appearance Anxiety Scale from baseline.

    The SAAS is a psychometrically validated measure of social anxiety about one's appearance.Possible scores range from 16 to 80, with higher scores indicating higher degree of social appearance anxiety.

    Time frame: Week4, Week12, Week24

  8. The changes in Facial Disability Index social/wellbeing function subscale from baseline

    Facial Disability Index(FDI) is a disease-specific, self-report instrument designed to evaluate the degree of disability in patients with facial nerve disorders.FDI includes 2 subscales: the FDI- physical function subscale and the FDI-social/ wellbeing function subscale.Possible scores of every subscale range from 0(worst) to 100(best).

    Time frame: Week4, Week12, Week24

  9. The changes in Facial Clinimetric Evaluation Scale from baseline.

    The FACE questionnaire is a validated instrument that is used to assess quality of life related to peripheral facial palsy. Possible scores range from 0(worst) to 100(best)

    Time frame: Week4, Week12, Week24

  10. The changes in visual analogue scale from baseline.

    Pain around the ear, in the face, or in the neck is assessed using VAS that ranged from 0 to 10 points, where 0 was no pain and 10 very severe pain.

    Time frame: Week4, Week8

  11. The proportion of participants with synkinesis.

    Time frame: Week 24

  12. The proportion of participants with facial spasm or contracture

    Time frame: Week 24

Other outcomes

  1. Evaluation of intradermal acupuncture expectation

    A brief 4-item Acupuncture Expectancy Scale score ranged from 4 to 20, with higher scores indicating greater expectancy.

    Time frame: Baseline

  2. Evaluation of guided self-rehabilitation management program expectation

    Participants will be asked to answer the following question: "Do you think GRMP is helpful for Bell's palsy?"

    Time frame: Baseline

  3. Evaluation of intradermal acupuncture compliance

    Compliance Rate=(actual treatment times/total treatment times) \*100%.

    Time frame: The 10th day after the onset of palsy until complete recovery or week 24

  4. Evaluation of guided self-rehabilitation management program compliance

    Compliance Rate=(actual session times/total session times) \*100%. For GRMP homework, we measure and quantify participants' adherence by the daily diary.

    Time frame: The 10th day after the onset of palsy until complete recovery or week 24

  5. Blinding assessment of intradermal acupuncture

    Participants will be asked the following question: do you think you have received active intradermal acupuncture in the past weeks?

    Time frame: Week 24

  6. Blinding assessment of guided self-rehabilitation management program

    Participants will be asked the following question: do you think you have received guided self-rehabilitation management program in the past weeks?

    Time frame: Week 24

  7. Adverse events assessment

    Adverse events and severe adverse events will be recorded in the case report form, whether related to interventions or not.

    Time frame: The 10th day after the onset of palsy to week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2029, 54 months after the start.

Of 38 non-industry interventional studies with no phase under Bell Palsy, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 54 months is above that.

Counting every sponsor, half of 40 studies reached it within 10 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2025
First posted
Jan 16, 2025
StartActual
Mar 24, 2025
Primary completionEst.
Sep 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06778473
Lead sponsor
Zhangjiagang First People's Hospital
Responsible party
Yang Jiang (Principal Investigator, Zhangjiagang First People's Hospital) — Principal investigator
First posted
Jan 16, 2025
Start date
Mar 24, 2025
Primary completion
Sep 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 30, 2025

Study contacts

yang Jiang, master
Contact
17768069362@163.com
17768069362
Dan Zhang, bachelor
Contact
18662237567@163.com
18662237567
yang Jiang, master
principal investigator · Zhangjiagang First People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion